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Abstract 
Introduction 
In patients with triple negative breast cancer (TNBC), over-expression of 
programmed death ligand 1 (PD-L1) on tumour-infiltrating immune cells 
(IC) increases the propensity for cancer cells to evade immune surveillance. 
Atezolizumab, a monoclonal antibody designed to inhibit PD-L1 enables T-
cell activation, restoring their ability to effectively detect and destroy tu-
mour cells.  
Methodology  
Published and grey literature were identified by searching the Cochrane Li-
brary, CRD Database, Embase, Ovid Medline, PubMed, Internet sites and 
contacting the manufacturer. Quality assessment was conducted to assess 
the risk of bias at the study level based on the EUnetHTA internal validity 
for randomized controlled trials. The magnitude of clinically meaningful 
benefit that can be expected from atezolizumab was evaluated based on, 
both the original and adapted version of, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology.  
Results of the IMpassion130 trial 
In the phase III, IMpassion130 trial, 902 treatment-naïve advanced TNBC 
patients were randomised 1:1 to 840 mg atezolizumab IV or placebo IV on 
days 1 and 15, plus 100 mg/m
2
 nab-paclitaxel IV on days 1, 8, and 15 of every 
28-day cycle, until disease progression or toxicity. Adding atezolizumab in-
creased the rate of progression-free survival (PFS) by 6%, prolonged median 
PFS by 1.7 months, and reduced the risk of progression or death by 20% 
compared to chemotherapy alone. In the PD-L1-positive subgroup, adding 
atezolizumab increased the rate of PFS by 13%, prolonged median PFS by 
2.5 months, and reduced the risk of progression or death by 38% compared 
to nab-paclitaxel alone. No statistically significant differences in overall sur-
vival (OS) were noted between groups (21.3 months atezolizumab- versus 
17.6 months placebo combination). Combination atezolizumab increased the 
objective response rate (ORR) and duration of response (DOR) in the inten-
tion-to-treat (ITT) and PD-L1-positive group compared to chemotherapy 
alone (10% versus 16%; 1.8 months versus 3.0 months, respectively. Atezoli-
zumab was associated with neutropenia, decreased neutrophils, peripheral 
neuropathy, fatigue, anaemia and immune-mediated adverse events. 
Conclusion 
Overall, adding atezolizumab to nab-paclitaxel as first-line therapy for ad-
vanced TNBC prolongs PFS and reduces the risk of progression or death. 
The PFS benefit of atezolizumab combination over chemotherapy alone was 
also consistent in the PD-L1-positive subgroup. These results are consistent 
with previous reports suggesting first-line atezolizumab, PD-L1 expression 
≥1, and >10% tumour-infiltrating IC are independently associated with in-
creased ORR and PFS. Mature OS data, quality of life measures, and a high-
er PD-L1 threshold are needed to ensure patients achieve a clinically rele-
vant benefit over time despite manageable toxicity. Further studies are 
needed to identify predictive immune biomarkers selective of responders, 
combination strategies that enhance tumour immunogenicity, and to deter-
mine whether these findings extend to other chemoimmunotherapy combi-
nations.  
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of 
Pharmaceuticals was used for structuring this report [1]. The Model organ-
ises HTA information according to pre-defined generic research questions. 
Based on these generic questions, the following research questions were an-
swered in the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is atezolizumab? 
A0022 Who manufactures atezolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has atezolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is advanced triple-negative breast cancer? 
A0004 What is the natural course of triple-negative breast cancer? 
A0006 What are the consequences of triple-negative breast cancer for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of disease or health condition? 
A0003 What are the known risk factors for triple-negative breast cancer? 
A0024 
How is triple-negative breast cancer currently diagnosed according to published guidelines 
and in practice? 
A0025 
How is triple-negative breast cancer currently managed according to published guidelines 
and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of atezolizumab on mortality? 
D0005 
How does atezolizumab affect symptoms and findings (severity, frequency) of triple-
negative breast cancer? 
D0006 
How does atezolizumab affect progression (or recurrence) of triple-negative breast 
cancer? 
D0011 What is the effect of atezolizumab on patients ̕ body functions? 
D0012 What is the effect of atezolizumab on generic health-related quality of life? 
D0013 What is the effect of atezolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is atezolizumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying atezolizumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of atezolizumab? 
A0021 What is the reimbursement status of atezolizumab? 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Atezolizumab/Tecentriq
®
/MPDL3280A 
 
B0001: What is atezolizumab? 
In patients with triple negative breast cancer (TNBC), over-expression of 
programmed death ligand 1 (PD-L1) on tumour-infiltrating immune cells 
(IC) increases the propensity for cancer cells to evade immune surveillance. 
Atezolizumab, a monoclonal antibody designed to inhibit PD-L1 enables T-
cell activation, restoring their ability to effectively detect and destroy tu-
mour cells [2].  
Atezolizumab is available in 1200 mg/20 mL (60 mg/mL) single-use vials. It 
is administered intravenously (IV) at a fixed dose of 840 mg on days 1 and 
15 of every 28-day cycle until disease progression or unacceptable toxicity. 
Patients also receive 100 mg/m
2
 nanoparticle albumin-bound (nab)-
paclitaxel IV on days 1, 8, and 15 per 28-day cycle for six cycles or more [3].  
Patients should be monitored for signs and symptoms of immune-mediated 
pneumonitis, hepatitis, colitis, endocrinopathies, infections or infusion reac-
tions. Atezolizumab may be withheld in patients with adverse events (AEs) 
of grade ≥2 severity until they are clinically stable, and corticosteroid dose 
is reduced to ≤10 mg/day. Permanently discontinue atezolizumab in pa-
tients with recurrent grade 3, 4 or life-threatening AEs; and those with per-
sistent grade ≥2 AEs or inability to taper corticosteroids within 12 weeks 
[4]. Immune-modulating drugs may interact with atezolizumab, and system-
ic corticosteroids may affect its efficacy [2]. 
 
A0022: Who manufactures atezolizumab? 
Genentech Inc, a subsidiary of F Hoffmann-La Roche Ltd 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Atezolizumab (Tecentriq
®
) is indicated, in combination with nab-
paclitaxel, for previously untreated advanced TNBC (aTNBC).  
 
 
anti-PD-L1 antibody, 
immune checkpoint 
inhibitor 
840 mg atezolizumab IV 
on days 1 and 15 + 100 
mg/m2 nab-paclitaxel IV 
on days 1, 8, and 15 of 
28-day cycle  
 
monitor for immune-
mediated AEs, infusion 
reactions and infections; 
withhold/ discontinue 
for safety/tolerability  
previously untreated 
aTNBC 
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4 Current regulatory status 
A0020: For which indications has atezolizumab received marketing authori-
sation? 
Atezolizumab received its first global approval by the US Food and Drug 
Administration (FDA) in May 2016 for the treatment of locally advanced or 
metastatic urothelial cancer (MUC) with disease progression during or fol-
lowing platinum-based chemotherapy. Approval was based on the tumour 
response rate and durability reported the single arm, two-cohort, phase II, 
IMvigor210 study [5]. Indications were expanded to include cisplatin-
ineligible and platinum-treated MUC patients following efficacy results 
from cohort 1 in April 2017. 
In June 2018, the FDA limited atezolizumab use to cisplatin-ineligible pa-
tients with PD-L1 tumour expression (PD-L1 stained tumour-infiltrating IC 
covering ≥5% of tumour area as determined by an FDA-approved test), or 
platinum-ineligible patients regardless of PD-L1 status. Limitations were 
made based on the decreased survival associated with atezolizumab mono-
therapy versus platinum-based chemotherapy observed in clinical trials in-
volving untreated MUC patients with low PD-L1 expression. In July 2018, 
the Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc) was 
FDA-approved as a complementary diagnostic required for patient selection 
[6].  
In October 2016, the FDA approved atezolizumab for the treatment of meta-
static non-small cell lung cancer (NSCLC) with progression during or fol-
lowing platinum-based chemotherapy. Patients with epidermal growth fac-
tor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour 
aberrations who progress following therapy for these aberrations may also 
receive atezolizumab. The approval was based on two international, random-
ized, open-label trials, OAK (phase III) and POPLAR (phase II) [7, 8]. In 
December 2018, the FDA approved atezolizumab in combination with 
bevacizumab, paclitaxel and carboplatin as first-line treatment for metastat-
ic NSCLC without EGFR or ALK aberrations. Approval was based on over-
all survival (OS) data from the phase III IMpower150 study [9].  
Atezolizumab received market authorization by the European Medical 
Agency (EMA) in September 2017 as monotherapy for previously treated, 
locally advanced or metastatic NSCLC, and for previously treated or cispla-
tin-ineligible MUC regardless of PD-L1 status [10]. In October 2018, the 
company withdrew its application to extend atezolizumab use in combina-
tion with bevacizumab for the treatment of advanced or metastatic renal cell 
carcinoma due to insufficient study results [11].  
The FDA recently granted priority review to atezolizumab in combination 
with nab-paclitaxel as first-line treatment for patients with locally advanced 
or metastatic PD-L1-positive TNBC. The phase III IMpassion130 trial 
forms the basis for the supplemental biologics license application (sBLA) 
that is scheduled for decision making by March 12, 2019 [12, 13]. Data from 
IMpassion130 are also under consideration by the EMA, with possible ap-
proval later in 2019 [14].  
FDA approvals: 
monotherapy for MUC 
in 2016; expanded to 
cisplatin-ineligible and 
platinum-treated MUC 
in 2017 
limited to PD-L1-positive 
cisplatin-ineligible MUC 
or platinum-ineligible 
MUC regardless of PD-L1 
status in 2018 
2nd-line metastatic 
NSCLC; in combination 
with bevacizumab, 
paclitaxel and 
carboplatin as first-line 
for metastatic NSCLC 
without EGFR/ALK 
aberrations    
EMA approvals:  
2nd-line metastatic 
NSCLC; pre-treated or 
cisplatin-ineligible MUC 
regardless of PD-L1 
status in 2017 
FDA and EMA pending 
approvals in 2019: in 
combination with nab-
paclitaxel as 1st-line for 
PD-L1-positive aTNBC 
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5 Burden of disease 
A0002: What is triple-negative breast cancer? 
TNBC is characterized by a lack of oestrogen- and progesterone receptor ex-
pression and does not overexpress human epidermal growth factor receptor 2 
(HER2). Without an approved targeted therapy for TNBC, chemotherapy re-
mains as first-line treatment. [15]. Compared to luminal breast cancers, 
TNBC is highly sensitive to chemotherapy (10–25% versus 30–40% complete 
response [CR]) due to higher levels of tumour-immune infiltrate. TNBC is 
molecularly subtyped as basal-like, mesenchymal, luminal androgen receptor 
positive and immunomodulatory. While these subtypes express different lev-
els of immune genes, all are immunogenic with high genetic instability, muta-
tional load and immune infiltrate [16]. In TNBC patients, the immune 
checkpoint inhibitor PD-L1 is over-expressed on tumour-infiltrating IC. 
PD-L1 binds ligand proteins resulting in T-cell suppression and evasion 
from immunosurveillance.  
 
A0004: What is the natural course triple-negative breast cancer? 
Breast cancer typically arises when epithelial cells lining the milk ducts 
and/or lobules undergo aberrant cell growth due to dysregulation of the cell 
cycle. In the early stages, atypical cells confined to the milk ducts are termed 
stage 0, ductal carcinoma in situ (DCIS). Stage I breast cancer is invasive 
but is restricted to the area where the first abnormal cells arose. While most 
breast cancers are diagnosed as stage I (localized to one area) or stage II (ear-
ly locally advanced), most TNBCs are diagnosed as invasive ductal carcino-
ma (IDC) or invasive lobular carcinoma (ILC), where abnormal cells have 
spread beyond the ducts or glands into the breast tissue [15, 17].  
Stage III, locally advanced breast cancer includes tumours larger than five 
centimetres in diameter that involve the skin, underlying muscle, lymph 
nodes or inflammatory breast cancer (IBC). Many TNBC are diagnosed as 
stage IV metastatic breast cancer, where breast cancer cells have travelled 
through the lymphatic system and blood stream forming metastatic tumours 
in the brain or lungs. TNBC is less likely to spread to the lymph nodes or 
bones than other breast cancers [15, 17]. 
 
A0006: What are the consequences of triple-negative breast cancer for the 
society? 
Globally, breast cancer is the most frequently diagnosed malignancy and the 
leading cause of cancer death in women worldwide [17]. TNBC accounts for 
approximately 15–20% of the breast cancers diagnosed worldwide, almost 
200,000 cases per year. Compared with other breast cancers, TNBC more 
commonly affects young, premenopausal women and may occur more fre-
quently in women with three or more children [15]. Patients with TNBC 
have a poorer prognosis than other types of breast cancer due to their higher 
grade, lack of targeted therapies, higher and earlier risk of relapse following 
standard chemotherapy. Recurrences often occur within the first three years 
after diagnosis with a high rate of visceral metastases. Despite their high 
chemosensitivity, the median OS of patients with TNBC rarely exceeds 12–
18 months [18].  
TNBC lacks ER, PR, and 
HER2 expression; 15-
20% of breast cancers 
immunogenic: PD-L1 
over-expression on 
tumour-infiltrating IC  
staged I-IV by 
invasiveness 
metastasize to  
brain and lungs 
commonly affects 
young, premenopausal 
women and those with 
>3 children 
 
recurrence within 1–3 
years of diagnosis; 
median OS <18 months 
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A0023: How many people belong to the target population? 
About 30% of all malignant neoplasm cases in Austria are due to breast can-
cer. Accounting for 17% of all deaths due to cancer, it is the most common 
cause of death due to cancer in women. Unlike other types of breast cancer 
that are commonly diagnosed in patients aged 60 or older, TNBC is more 
likely to be diagnosed in people younger than 50 years of age [15]. The age 
standardised incidence rate for the European Standard Population (2015) is 
116.7 for women and 2.4 for men per 100,000 persons per year. In 2015, 5,390 
women and 90 men were diagnosed with breast cancer in Austria, and 1,568 
women and 22 men died of the disease [19]. TNBC accounts for approxi-
mately 15–20% of breast cancers; therefore about 822 to 1,096 persons diag-
nosed with breast cancer in 2015 in Austria were affected by triple-negative 
disease.  
 
A0005: What are the symptoms and the burden of triple-negative breast can-
cer? 
Symptoms of TNBC may include a hard, immovable lump in the breast with 
irregular borders. Patients with locally advanced breast cancer may experi-
ence dimpling or thickening of the skin, a change in shape or colour, nipple 
inversion or discharge, a pain in the breast or armpit. Patients with meta-
static breast cancer may experience bone pain, fractures, headaches, sei-
zures, swollen lymph nodes, shortness of breath or jaundice depending on 
the organs involved [17]. 
 
A0003: What are the known risk factors for triple-negative breast cancer? 
Risk factors associated with the diagnosis of TNBC include younger age, 
BReast CAncer (BRCA) gene mutation, race, premenopausal status, mater-
nal-related factors and obesity [15, 20]. Women under 40 years of age may 
have a twofold higher risk of TNBC than women over 50 years of age [21]. 
While less than 6% of all breast cancers are BRCA-related, up to 20% of pa-
tients with TNBC carry BRCA1/2 mutations. TNBC was highly predictive 
of BRCA1 mutation status for women less than 50 years of age and modestly 
predictive of positive BRCA2 mutation status in women 50 years of age or 
older [22]. The incidence of TNBC is higher in premenopausal and African-
American or Hispanic women compared to menopausal and Caucasian 
women [15]. Evidence suggests that nulliparity is associated with a lower 
risk of TNBC; however, parity was not protective in African-American wom-
en. Obesity was associated with an increased risk of TNBC according to a 
meta-analysis of eleven studies involving 24,479 women [23].  
 
 
 
 
 
 
 
TNBC in Austria: ~822–
1,096 cases in 2015 
 
116.7/100,000 
women/year  
European Standard 
Population 2015 
symptoms include 
breast lump, thickening, 
and pain 
risk factors: young age, 
obesity, African 
American, Hispanic, 
premenopausal and 
BRCA mutation status 
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A0024: How is triple-negative breast cancer currently diagnosed according 
to published guidelines and in practice? 
Since TNBC presents aggressively with rapid growth, it is more likely to be 
diagnosed clinically than mammographically compared to ER-positive can-
cers. A mammogram of both breasts is performed to define tumour size and 
assess whether the contralateral breast is affected. Breast magnetic imaging 
(MRI) or ultrasound may also be performed to estimate tumour size and dis-
tinguish a fluid-filled or a solid mass. During a biopsy, a sample of breast 
cells or tissue from the lump is examined to determine the presence of can-
cer cells, and levels of expression of hormone receptors and HER2 protein. 
TNBC is defined as hormone receptor negative (<1% staining of tumour 
cells by immunohistochemistry) and HER2 negative (0–1+ immunohisto-
chemistry or nonamplified using fluorescence in-situ hybridization), form-
ing the basis for clinical management. Women 60 years of age or younger di-
agnosed with TNBC also undergo BRCA mutation testing regardless of fam-
ily history. Bone scans, blood tests, computed tomography (CT) and posi-
tron-emission tomography (PET) scans may be conducted to determine 
whether breast cancer has spread to bone, liver, lungs, or brain [17].  
 
 
6 Current treatment 
A0025: How is triple-negative breast cancer currently managed according to 
published guidelines and in practice? 
Previously untreated metastatic and advanced TNBC is typically treated 
using chemotherapy. While there is no standard, specific chemotherapy 
regimen for TNBC, anthracycline, alkylator-, and taxane-based chemo-
therapies are commonly used [15]. 
 International guidelines support the use of single-agent taxanes or 
anthracyclines (doxorubicin, paclitaxel). Other possible regimens in-
clude gemcitabine, eribulin, capecitabine, or vinorelbine as first-line 
therapy [24].  
 Combination regimens include AC (doxorubicin + cyclophospha-
mide), EC (epirubicin + cyclophosphamide), CMF (cyclophospha-
mide + methotrexate + fluorouracil), docetaxel + capecitabine, GT 
(gemcitabine + paclitaxel), gemcitabine + carboplatin, and paclitax-
el + bevacizumab [24]  
 A platinum agent or taxane chemotherapy is a suitable option to treat 
BRCA carriers with chemotherapy-naïve aTNBC [15]. 
 Polyadenosine diphosphate-ribose polymerase inhibitor (PARPi), 
olaparib, was recently approved to treat advanced or metastatic 
TNBC in those patients with BRCA1/2 mutations who have previous-
ly been treated with chemotherapy [15, 24]. 
 
 
diagnostics: 
mammography, biopsy, 
HR and HER2 status, 
bone, CT, PET scans 
 
 
 
 
 
 
 
 
BRCA mutation testing 
for women ≤60 years 
no standard 
chemotherapy regimen: 
single-agent taxane or 
anthracycline 
PARPi: olaparib is 
approved for advanced 
or metastatic TNBC 
with BRCA1/2 mutations  
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7 Evidence 
A literature search was conducted on 15 January 2019 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “atezolizumab”, “Tecentriq”, “breast cancer”, “breast car-
cinoma”, “triple negative” and “advanced”. The manufacturer was also con-
tacted and submitted three references (all of which had already been identi-
fied by systematic literature search [13, 25, 26]). A manual search identified 
three FDA regulatory documents [4, 6, 12], three EMA reports [10, 11, 14], 
ten clinical management documents [5, 7-9, 15, 17, 21-24], one statistical 
document [19], and two cost documents [27, 28]. 
Overall, 114 references were identified. Included in this reported are:  
 IMpassion130, phase III [3, 13, 29, 30] 
 Clinical outcomes and biomarker analyses of atezolizumab for met-
astatic TNBC, phase I [31] 
 
 Atezolizumab plus nab-paclitaxel in metastatic TNBC, phase Ib 
[32] 
To assess the risk of bias at the study level, the assessment of the methodo-
logical quality of the evidence was conducted based on the EUnetHTA in-
ternal validity for randomised controlled trials (RCTs) [33]. Evidence was 
assessed based on the adequate generation of the randomisation sequence, 
allocation concealment, blinding of patient and treating physician, selective 
outcome reporting and other aspects that may increase the risk of bias. 
Study quality details are reported in Table 6 and Table 5 of the Appendix. 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effective-
ness assessment of pharmaceuticals, considering the following elements: 
population, intervention, comparator, outcomes and setting (Table 5) [34]. 
To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale developed by the European Society for Medical Oncology (ESMO-
MCBS) was used [35]. Additionally, an adapted version (due to perceived 
limitations) of the ESMO-MCBS was applied [36]. Details of the magnitude 
of the clinically meaningful benefit scale are reported in Table 3. 
 
systematic literature 
search in 5 databases:  
95 hits 
 
 
manual search: 19 
additional references 
overall: 114 references 
included: 3 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
applicability of evidence 
magnitude of clinically 
meaningful benefit 
assessed based on 
ESMO-MCBS 
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7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality cri-
teria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in 
clinical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The 
final version and the policy recommendations are under full responsibility 
of the LBI-HTA. 
 
7.2 Clinical efficacy and safety –  
phase III studies 
IMpassion130 (NCT02425891) is a multicentre, randomised, double-blind, 
interventional phase III trial involving 902 patients with unresectable local-
ly advanced or metastatic TNBC [13]. The study was designed to evaluate 
whether adding atezolizumab to nab-paclitaxel as first-line therapy for ad-
vanced or metastatic TNBC prolonged progression-free survival (PFS) and 
OS compared to placebo plus nab-paclitaxel. Efficacy analyses were based 
on all randomly assigned patients comprising the intent-to-treat (ITT) popu-
lation and the PD-L1-positive subgroup. Safety analyses involved all pa-
tients who received at least one dose of treatment.  
Eligible patients were 18 years or older, with untreated metastatic or unre-
sectable locally advanced, histologically documented TNBC, and had tu-
mour specimens available for centralised PD-L1 testing. Patients must have 
had measureable disease per Response Evaluation Criteria in Solid Tu-
mours (RECIST, version 1.1) and Eastern Cooperative Oncology Group 
(ECOG) performance-status of 0 or 1, with adequate hematologic and organ 
function. Patients were excluded if they had a history of autoimmune dis-
ease, untreated central nervous system (CNS) disease, or were previously 
treated with immune checkpoint-targeting therapies, immunosuppressants, 
systemic immunostimulatory agents or glucocorticoids. Tumour specimens 
were evaluated for PD-L1 expression using the Ventana PD-L1 (SP142) 
immunohistochemical assay. Eligible patients were stratified by baseline 
liver metastases (present or absent), neoadjuvant or adjuvant taxane treat-
ment (use or nonuse), and PD-L1 expression status on tumour-infiltrating 
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
 
IMpassion130: 
atezolizumab + nab-
paclitaxel versus placebo 
+ nab-paclitaxel as first-
line for aTNBC 
ITT (n = 902):  
stratified by baseline 
liver metastases, 
neoadjuvant/adjuvant 
taxane treatment, and 
PD-L1 status  
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immune cells as a percentage of tumour area (<1% PD-L1 negative versus 
≥1% PD-L1 positive).  
Patients were randomised 1:1 to 840 mg atezolizumab IV or placebo IV on 
days 1 and 15 plus 100 mg/m
2
 nab-paclitaxel IV on days 1, 8, and 15 of every 
28-day cycle for six cycles or more, until disease progression or unacceptable 
toxicity. In the absence of progression, atezolizumab, placebo or nab-
paclitaxel could be discontinued independently, due to toxicity. While dose 
reductions of atezolizumab or placebo were not permitted, dosage may be in-
terrupted or discontinued due to AEs. Pre-specified modifications of the 
nab-paclitaxel dose were permitted to manage toxicity. For patients in the 
atezolizumab plus nab-paclitaxel group, the median treatment duration 
(DOT) was 24.1 weeks for atezolizumab and 22.1 weeks for nab-paclitaxel. 
Patients in the placebo combination group had median treatment duration 
of 22.1 weeks for placebo and 21.8 weeks for nab-paclitaxel. The mean (± 
standard deviation) cumulative dose of nab-paclitaxel was 1,980.0 ± 1,303.1 
mg/m
2
 in the atezolizumab combination group and 1,764.4 ± 1,238.3 mg/m
2
 
in the placebo combination group.  
The two primary efficacy co-endpoints were investigator-assessed PFS and 
OS within the ITT population and the PD-L1-positive subgroup. Secondary 
endpoints included PFS assessed by independent central review (ICR), in-
vestigator-assessed objective response rate (ORR), duration of response 
(DOR), and safety. AEs were graded for severity according to the National 
Cancer Institute Common Terminology Criteria (CTCAE) version 4.0. Tu-
mours were assessed every eight weeks for twelve months, and every twelve 
weeks thereafter. Patients were followed-up for survival every three months 
after discontinuing the intervention. The median follow-up (for both arms) 
was 12.9 months in the ITT population at the time of primary analysis.  
The ITT population (n = 902) had a median age of 56 years (range 20–86), 
99.6% were female, 67.5% were Caucasian, 63.2% were previously treated 
with neoadjuvant or adjuvant therapy, 27.1% had baseline liver metastases, 
and 41.4% had an ECOG status of 1. The PD-L1-positive subgroup (n = 
369) had a median age of 53 years (range 26 to 85), 99.8% were female, 
68.9% were Caucasian, 65.6% received previous neoadjuvant or adjuvant 
therapy, 22.5% had baseline liver metastases, and 80.7% had an ECOG sta-
tus of 1. Detailed patient characteristics including inclusion- and exclusion 
criteria can be found in Table 5 and study quality is described in Table 6 of 
the appendix, respectively. Clinical efficacy data are presented in Table 1 
and AEs are listed in Table 2.  
 
 
 
 
 
 
 
 
840 mg atezolizumab IV 
or placebo IV on days 1 
and 15 + 100 mg/m2 
nab-paclitaxel IV on 
days 1, 8 and 15 every 
28-days for ≥6 cycles 
 
median DOT: 24.1 weeks 
for atezolizumab versus 
22.1 weeks for placebo 
primary co-endpoints:  
investigator-assessed 
PFS and OS in ITT and 
PD-L1-positive subgroup 
 
secondary endpoints: 
ORR, DOR, and safety 
ITT: median age 56 
years, 63% had 
neoadjuvant/adjuvant 
therapy, 27% had 
baseline liver metastases 
 
PD-L1-positive: median 
age 53 years, 66% had 
neoadjuvant/adjuvant 
therapy, 23% baseline 
liver metastases 
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7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of atezolizumab on mortality? 
In the ITT population, 40.1% (181/451) patients in the atezolizumab combi-
nation group and 46.1% (208/451) patients in the placebo combination 
group had died as of April 17, 2018. At interim analysis, the primary co-
endpoint of investigator-assessed median OS was 21.3 months in the atezoli-
zumab plus nab-paclitaxel group versus 17.6 months in the placebo plus 
nab-paclitaxel group (stratified hazard ratio [SHR] for death, 0.84, 95% con-
fidence interval [CI] 0.69–1.02; p = 0.08, no statistical significant difference 
[NSSD]).  
In the PD-L1-positive subgroup, 34.6% (64/185) patients in the atezoli-
zumab combination group and 47.8% (88/184) in the placebo combination 
group had died as of the data cut-off. In the PD-L1 subgroup, Kaplan-Meier 
analysis revealed a median OS of 25.0 months in the atezolizumab plus nab-
paclitaxel group and 15.5 months in the placebo plus nab-paclitaxel group 
(SHR for death, 0.62, 95% CI 0.45–0.86; not formally tested [NFT]). 
 
D0006: How does atezolizumab affect progression (or recurrence) of triple-
negative breast cancer? 
In the ITT population, 79.4% (n = 358) of patients receiving atezolizumab 
combination and 83.8% (n = 378) of patients receiving placebo combination 
experienced disease progression or death at a median follow-up of 12.9 
months. The primary co-endpoint of investigator-assessed median PFS was 
7.2 months with atezolizumab plus nab-paclitaxel versus 5.5 months with 
placebo plus nab-paclitaxel (SHR for progression or death, 0.80, 95% CI 
0.69–0.92; p = 0.002).  
The PFS benefit of atezolizumab combination over placebo combination was 
demonstrated across most subgroups as defined on the basis of trial stratifi-
cation factors. In the PD-L1-positive subgroup, 74.6% (n = 138/185) pa-
tients receiving atezolizumab combination and 85.3% (n = 157/184) of pa-
tients receiving placebo combination experienced progression or death. The 
median PFS was 7.5 months with atezolizumab plus nab-paclitaxel versus 
5.0 months with placebo plus nab-paclitaxel (SHR for progression or death, 
0.62, 95% CI 0.49–0.78; p < 0.001).           
 
D0005: How does atezolizumab affect symptoms and findings (severity, fre-
quency) of triple-negative breast cancer? 
The secondary endpoint of investigator-assessed ORR was 56.0% in the ate-
zolizumab combination group and 45.9% in the placebo combination group 
(p = 0.002) for the ITT population. A CR was reported in 7.1% of atezoli-
zumab combination versus 1.6% of placebo combination recipients. In the 
PD-L1 subgroup, the ORR was 58.9% with atezolizumab plus nab-paclitaxel 
and 42.6% with placebo plus nab-paclitaxel. CRs were reported by 10.3% of 
patients receiving atezolizumab combination versus 1.1% of patients receiv-
ing placebo combination.  
median OS ITT: 21.3 
months for 
atezolizumab versus 
17.6 months for placebo; 
not statistically 
significant 
 
 
 
 
 
median OS PD-L1-
positive: 25.0 months 
for atezolizumab versus 
15.5 months for placebo; 
NFT 
 
median PFS ITT: 7.2 
months for 
atezolizumab versus 5.5 
months for placebo 
 
 
 
 
 
median PFS PD-L1-
positive: 7.5 months for 
atezolizumab versus 5.0 
months for placebo  
ORR ITT: 56.0% 
atezolizumab versus 
45.9% placebo  
 
ORR PD-L1-positive: 
58.9% atezolizumab 
versus 42.6% placebo   
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In the ITT population, the median DOR was 7.4 months in the atezolizumab 
plus nab-paclitaxel group and 5.6 months in the placebo plus nab-paclitaxel 
group. The median DOR in the PD-L1-positive subgroup was 8.5 months 
with atezolizumab combination versus 5.5 months with placebo combina-
tion.  
 
D0011: What is the effect of atezolizumab on patients̕ body functions? 
Atezolizumab may affect body functions by causing immune-mediated AEs 
including pneumonitis, hepatitis, colitis, endocrinopathies, and infections 
[4, 30]. Adverse events of special interest (AESIs) that were thought to be 
immune-related occurred in 57.3% of atezolizumab plus nab-paclitaxel re-
cipients and 41.8% of placebo plus nab-paclitaxel recipients. AESIs of grade 
≥3 severity were reported in 7.5% of the atezolizumab combination group 
and 4.3% of the placebo combination group. Two grade 5 AESI were report-
ed; an atezolizumab combination recipient had autoimmune hepatitis and 
one placebo combination recipient experienced hepatic failure. Immune-
related hypothyroidism occurred at a higher frequency in the atezolizumab 
plus nab-paclitaxel group than in the placebo plus nab-paclitaxel group 
(17.3% versus 4.3%, respectively). Pneumonitis occurred in 3.1% of patients 
receiving atezolizumab combination versus 0.2% of those receiving placebo 
combination [13]. Atezolizumab may cause foetal harm based on its mecha-
nism of action.  
 
D0012: What is the effect of atezolizumab on generic health-related quality 
of life? 
No evidence was reported regarding the effect of atezolizumab on generic 
health-related quality of life (QoL).  
 
D0013: What is the effect of atezolizumab on disease-specific quality of life? 
No evidence was reported regarding the effect of atezolizumab on disease-
specific QoL. 
 
 
 
 
 
 
 
 
 
 
 
 
DOR ITT: 7.4 months for 
atezolizumab versus 5.6 
months for placebo 
immune-mediated AEs: 
pneumonitis, hepatitis, 
colitis, and 
endocrinopathies 
 
 
 
 
 
immune-related 
hypothyroidism 17.3% 
(versus 4.5%) 
 
foetal toxicity 
health-related QoL:  
no evidence 
disease-specific QoL:  
no evidence 
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Table 1: Efficacy results of Impassion130 [13, 25, 30]17 
Abbreviations: CI = confidence interval; HR = hazard ratio; ICR = independent central review; m = months; n = number; N = total number; NFT = not 
formally tested; NR = not reported; NSD = no statistically significant difference; OR = odds ratio; OS = overall survival; PFS = progression-free survival; 
SHR = stratified hazard ratio 
 
Descriptive sta-
tistics and 
estimate varia-
bility 
Treatment group 
Atezolizumab + nab-
paclitaxel 
(n = 451) 
Placebo + nab-paclitaxel 
(n = 451) 
Investigator-assessed median OS, ITT (n = 902), m (95% CI) 
Rate of death at 12.9 m, ITT, n/N (%) 
  Median OS, PD-L1-positive (n = 369), m (95% CI) 
  Rate of death at 12.9 m, PD-L1-positive, n/N (%) 
21.3 (17.3–23.4) 
181/451 (40.1) 
25.0 (22.6–NE) 
64/185 (34.6) 
17.6 (15.9–20.0) 
208/451 (46.1) 
15.5 (13.1–19.4) 
88/184 (47.8) 
Investigator-assessed median PFS, ITT, m (95% CI) 
Rate of PFS at 12 m, ITT, % (95% CI) 
Rate of disease progression/death at 12.9 m, n/N (%) 
  Median PFS, PD-L1-positive, m (95% CI) 
  Rate of PFS at 12 m, PD-L1-positive, % (95% CI) 
  Rate of disease progression/death, PD-L1-positive, n/N (%) 
7.2 (5.6–7.5) 
23.7 (19.6–27.9) 
358/451 (79.4) 
7.5 (6.7–9.2) 
29.1 (22.2–36.1) 
138/185 (74.6) 
5.5 (5.3–5.6) 
17.7 (14.0–21.4) 
378/451 (83.8) 
5.0 (3.8–5.6) 
16.4 (10.8–22.0) 
157/184 (85.3) 
Investigator-assessed ORR, ITT n, %, (95% CI) 
  CR, ITT, n, % (95% CI)  
  ORR, PD-L1-positive, n, % (95% CI) 
  CR, PD-L1-positive, n, % (95% CI) 
252, 56.0 (51.3–60.6) 
32, 7.1 (4.9–9.9) 
109, 58.9 (51.5–66.1) 
19, 10.3 (6.3–15.6) 
206, 45.9 (41.2–50.6) 
7, 1.6 (0.6–3.2) 
78, 42.6 (35.4–50.1) 
2, 1.1 (0.1–3.9) 
Median DOR, ITT, m (95% CI) 
  Median DOR, PD-L1 positive, m (95% CI) 
7.4 (6.9–9.0) 
8.5 (7.3–9.7) 
5.6 (5.5–6.9) 
5.5 (3.7–7.1) 
Effect  
estimate per 
comparison 
 
Comparison groups                                                                                    Atezolizumab combination versus placebo combination 
Investigator-assessed OS, ITT (n = 902) 
(primary endpoint) 
SHR for death 0.84 
95% CI 0.69–1.02 
Log-rank test p-value 0.08 NSSD 
OS, PD-L1-positive  
(subgroup analysis, n = 369) 
SHR  0.62 
95% CI 0.45–0.86 
Log-rank test p-value NFT 
Investigator-assessed PFS, ITT  
(primary endpoint) 
SHR for death/progression 0.80 
95% CI 0.69–0.92 
Log-rank test p-value 0.002 
ICR-assessed PFS, ITT 
(secondary endpoint) 
SHR for death/progression 0.78 
95% CI 0.67–0.91 
Log-rank test p-value NR 
PFS, PD-L1-positive 
(subgroup analysis, n = 369) 
SHR for death/progression 0.62 
95% CI 0.49–0.78 
Log-rank test p-value <0.001 
ICR-assessed PFS, PD-L1-positive 
(secondary endpoint, subgroup analysis, n = 369) 
SHR for death/progression 0.63 
95% CI 0.49–0.81 
Log-rank test p-value NR 
OR, ITT 
(secondary endpoint) 
OR 1.52  
95% CI 1.16–1.97 
Log-rank test p-value 0.002, NSSD alpha < 0.1% 
OR, PD-L1-positive 
(secondary endpoint, subgroup analysis, n = 369) 
OR 1.96 
95% CI 1.29-2.98 
Log-rank test p-value 0.002, NSSD alpha < 0.1% 
DOR, ITT  
(secondary endpoint) 
HR  0.78 
95% CI 0.63–0.98 
Log-rank test p-value NR 
DOR, PD-L1-positive 
(secondary endpoint, subgroup analysis n = 369) 
HR  0.60 
95% CI 0.43–0.86 
Log-rank test p-value NR 
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7.2.2 Safety 
 
C0008: How safe is atezolizumab in relation to the comparator(s)? 
In the safety population (n = 890), investigator-assessed AEs were more 
commonly reported in the atezolizumab- than placebo combination group, 
regardless of attribution (99.3% versus 97.9%, respectively). The most com-
mon AEs were similar between groups, with alopecia being the most com-
mon in both groups (56.4% versus 57.5%). AEs that occurred with 5% or 
greater frequency in the atezolizumab- versus placebo combination group 
include nausea, cough, neutropenia, pyrexia and hypothyroidism. 
AEs of grade 3 or 4 occurred in 48.7% of atezolizumab combination versus 
42.2% of placebo combination recipients; neutropenia, decreased neutro-
phils, peripheral neuropathy, fatigue and anaemia were most commonly re-
ported.  Peripheral neuropathy of grade 3 or 4 was more frequently reported 
in the atezolizumab- than placebo combination group (5.5% versus 2.7%, re-
spectively). Serious adverse events (SAE) occurred in 22.8% of atezolizumab 
plus nab-paclitaxel recipients and 18.3% of placebo plus nab-paclitaxel re-
cipients. Fatal AEs occurred in six patients (1.3%) receiving atezolizumab 
plus nab-paclitaxel and three (0.7%) of patients receiving placebo plus nab-
paclitaxel. There were three deaths due to autoimmune hepatitis, mucosal 
inflammation and septic shock amongst atezolizumab combination recipi-
ents, and one due to hepatic failure in a the placebo combination group.  
 
C0002: Are there harms related to dosage or frequency of applying 
atezolizumab? 
Approximately 15.9% of atezolizumab combination patients and 8.2% of 
placebo combination patients discontinued all trial drugs due to AEs, while 
6.4% and 1.4% discontinued atezolizumab and placebo, respectively. AEs 
were responsible for any dose reduction or interruption in 46.9% of 
atezolizumab combination patients and 40.4% of placebo combination 
patients, while 30.8% and 23.5% interrupted their atezolizumab or placebo 
dose, respectively.  
Atezolizumab may cause severe or life-threatening infusion-related reactions 
[4]. No statistically significant difference in the frequency of infusion 
reactions was noted between groups (1.1% for atezolizumab combination 
versus 1.1% for placebo combination) [30].  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of atezolizumab? 
Study participants had a median age of 56 years (range 20 to 86) with good 
performance status (ECOG performance 0 or 1), and adequate hematologic 
and organ function. Patients with a history of autoimmune disease were ex-
cluded from study. Clinical specificity of older patients and those with 
comorbidities, co-medications, reduced functional reserve, and immunose-
nescence may affect the efficacy and/or toxicity of immune-checkpoint in-
hibitors in this population. Immune-mediated AE may be more challenging 
in older patients due to reduced functional reserve and age-associated co-
morbidities [37].  
common AEs: alopecia, 
nausea, cough, 
neutropenia, pyrexia, 
and hypothyroidism 
common grade ≥3 AEs: 
peripheral neuropathy 
 
SAEs: 22.8% for 
atezolizumab versus 
18.3% for placebo 
30.8% interrupted dose 
and 6.4% discontinued 
due to AEs  
infusion reactions: no 
statistically significant 
difference between 
groups 
susceptibles: elderly, 
immune compromised, 
comorbid, reduced 
functional status 
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Atezolizumab may impair fertility, cause foetal harm and potentially SAEs 
in nursing infants. Females are advised to use of effective contraception and 
not to breastfeed during treatment and for at least five months following 
treatment.  
 
Table 2: Most frequent adverse events [13, 25, 30] 
Adverse Event (according  
to CTCAE version 4.0) 
Atezolizumab + Nab-Paclitaxel 
 (n = 452) 
Placebo + Nab-Paclitaxel  
(n = 438) 
Event 
Any Grade  
n (%) 
Grade 3 or 4 
n (%) 
Any Grade  
n (%) 
Grade 3 or 4 
n (%) 
Any regardless of attribution 449 (99.3) 220 (48.7) 429 (97.9) 185 (42.4) 
Treatment-related AEs 436 (96.5) 179 (39.6) 410 (936) 132 (30.1) 
SAEs 103 (22.8) 78 (17.0) 80 (18.3) 56 (13.0) 
AESI (potentially immune-related) 259 (57.3) 34 (7.5) 183 (41.8) 19 (4.3) 
Alopecia 255 (56.4) 3 (0.7) 252 (57.5) 1 (0.2) 
Fatigue 211 (46.7) 18 (4.0) 196 (44.7) 15 (3.4) 
Nausea 208 (46.0) 5 (1.1) 167 (38.1) 8 (1.8) 
Diarrhoea 147 (32.5) 6 (1.3) 150 (34.2) 9 (2.1) 
Anaemia 125 (27.7) 13 (2.9) 115 (26.3) 13 (3.0) 
Constipation  113 (25.0) 3 (0.7) 108 (24.7) 1 (0.2) 
Cough 112 (24.8) 0 (0.0) 83 (18.9) 0 (0.0) 
Headache 105 (23.2) 2 (0.4) 96 (21.9) 4 (0.9) 
Peripheral neuropathy 98 (21.7) 25 (5.5) 97 (22.1) 12 (2.7) 
Neutropenia 94 (20.8) 37 (8.2) 67 (15.3) 36 (8.2) 
Decreased appetite 91 (20.1) 3 (0.7) 79 (18.0) 3 (0.7) 
Vomiting 88 (19.5) 4 (0.9) 74 (16.9) 5 (1.1) 
Pyrexia 85 (18.8) 3 (0.7) 47 (10.7) 0 (0.0) 
Arthralgia 81 (17.9) 1 (0.2) 70 (16.0) 1 (0.2) 
Rash 78 (17.3) 2 (0.4) 72 (16.4) 2 (0.5) 
Dyspnoea 72 (15.9) 4 (0.9) 64 (14.6) 3 (0.7) 
Peripheral sensory neuropathy 72 (15.9) 9 (2.0) 52 (11.9) 8 (1.8) 
Peripheral oedema 66 (14.6 ) 1 (0.2) 68 (15.5) 6 (1.4) 
Myalgia 64 (14.2) 2 (0.4) 67 (15.3) 3 (0.7) 
Back pain 69 (15.3) 6 (1.3) 58 (13.2) 2 (0.5) 
Dizziness  63 (13.9) 0 (0.0) 47 (10.7) 0 (0.0) 
Dysgeusia 62 (13.7) 0 (0.0) 60 (13.7) 0 (0.0) 
Hypothyroidism 62 (13.7) 0 (0.0) 15 (3.4) 0 (0.0) 
I-M hypothyroidism 78 (17.3) 0 (0.0) 19 (4.3) 0 (0.0) 
Pruritus 62 (13.7 ) 0 (0.0) 45 (10.3) 0 (0.0) 
Decreased neutrophils 57 (12.6) 21 (4.6) 48 (11.0) 15 (3.4) 
Asthenia 56 (12.4) 2 (0.4) 50 (11.4) 4 (0.9) 
Urinary tract infection 53 (11.7) 4 (0.9) 46 (10.5) 2 (0.5) 
Insomnia 51 (11.3) 0 (0.0) 51 (11.6) 3 (0.7) 
Pain in extremity 49 (10.8) 2 (0.4) 43 (9.8) 1 (0.2) 
Nasopharyngitis 49 (10.8) 0 (0.0) 37 (8.4) 0 (0.0) 
Upper RTI 48 (10.6) 5 (1.1) 40 (9.1) 0 (0.0) 
Increased ALT 47 (10.4) 8 (1.8) 40 (9.1) 5 (1.1) 
Abdominal pain 46 (10.2) 2 (0.4) 53 (12.1) 1 (0.2) 
Hypertension 22 (5.0) 4 (1.0) 24 (5.0) 11 (3.0) 
Abbreviations: AE = adverse event; AESI = adverse events of special interest; ALT = alanine aminotransferase; CTCAE = Common 
Terminology for Cancer Adverse Events; I-M = immune-mediated; PLC = placebo; RTI = respiratory tract infection; SAE = serious 
adverse events 
atezolizumab may cause 
foetal harm 
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7.3 Clinical effectiveness and safety –  
further studies 
NCT01375842 is a multicentre, open-label, dose-escalation, phase I study to 
evaluate the safety and efficacy, of atezolizumab monotherapy in 116 pa-
tients with previously treated TNBC, and biomarkers associated with out-
comes [31]. Patients received 15–20 mg/kg atezolizumab IV every 3 weeks 
until unacceptable toxicity or loss of clinical benefit. The primary endpoint 
was safety and tolerability; secondary outcomes included ORR, DOR, PFS, 
and OS in the ITT population and key subgroups. PD-L1 expression was 
evaluated on IC and tumour cells (TC) using the Ventana SP142 immuno-
histochemical assay, and classified based on the percentage of PD-L1-
positive IC (IC3 = >10%, IC2 = 5–10%, IC1 = 1–5%, and IC0 = <1%) and 
TC (TC0 = <1% and TC1/2/3 = ≥1%). The median DOT was 2.1 months 
(range 0.4–45.6), with a median of four cycles (range 1–58).  
The ITT population (n = 116) had a median age of 53 years (range 29–82), 
98% had an ECOG status of 0 or 1, 65% had visceral metastases, and 58% 
had received at least two lines of prior therapy for metastatic TNBC. Ap-
proximately 78% (n = 91) had PD-L1 IC1/2/3 tumours, of which 19 and 72 
were treated in the first- and second-line and beyond setting. Approximately 
18% (n = 21) had PD-L1 IC0 tumours, of which two and 19 were treated in 
the first-and second-line and beyond setting, respectively.  
The ORR for the cohort was 10% (11/115; CI 4.9–16.5). Patients who re-
ceived first-line atezolizumab had an ORR of 24% (5/21; CI 8.2–47.2); those 
who received atezolizumab as second-line and beyond had an ORR of 6% 
(6/94; CI 2.4–13.4). The median DOR was 21 months (range 3 to ≥38 
months). Median PFS was 1.4 months (95% CI 1.3–1.6) by RECIST. In first-
line patients, median OS was 17.6 months (95% CI 10.2–not estimable), 
while second-line patients had a median OS of 7.3 (95% CI 6.1–10.8). Re-
sponse rates and OS were statistically significantly higher in patients with 
PD-L1 expression of at least 1% on IC (ORR = 12%, OS = 10.1 months, re-
spectively) compared to patients with less than 1% PD-L1 expression (ORR 
= 0%, median OS = 6.0 months, respectively). High levels of ICs (>10%) 
were independently associated with higher ORR and longer median OS. 
Treatment-related AEs occurred in 63% of patients, 79% were of grade 1 to 
2, and most occurred within the first year of treatment.  
NCT01633970 is a multicentre, multi-cohort, open-label, phase Ib designed 
to assess the safety and efficacy of atezolizumab plus chemotherapy in ad-
vanced solid tumours. One cohort involved 33 women with metastatic TNBC 
treated with atezolizumab plus nab-paclitaxel [32]. Patients received 800 mg 
atezolizumab IV on day’s 1 and 15, and 125 mg/m2 nab-paclitaxel IV on days 
1, 8 and 15 of every 28-day cycle until disease progression or unacceptable 
toxicity. Primary endpoints were safety and tolerability; secondary outcomes 
included pharmacokinetics, ORR, DOR, disease control rate (DCR), PFS, 
OS and biomarker analysis. Tumour assessments occurred every 2 cycles for 
the first year, and every 4 cycles thereafter. PD-L1 expression was centrally 
assessed using the Ventana SP142 immunohistochemical assay. The median 
DOT was 5.6 months (range 0–30) for atezolizumab and 4.7 months (range 
0–24), for nab-paclitaxel. The study cohort (n = 33) had a median age of 55 
years (range 32–84), 76% were Caucasian, 82% had ECOG status 1, 58% had 
NCT01375842: 
atezolizumab 
monotherapy in 116 
metastatic TNBC 
patients 
cohort: 53 years, 65% 
visceral metastases, 
58% ≥2 prior therapies  
 
PD-L1 IC1/2/3: 78% PD-
L1 IC0: 18%  
ORR and OS PD-L1-
positive: 12% and  
10.1 months 
 
ORR and OS PD-L1-
negative: 0% and 6 
months 
 
>10% IC and first-line 
associated with higher 
ORR and OS 
 
AEs: 63% grade 1 or 2 
NCT01633970: 
atezolizumab + nab-
paclitaxel in 33 
metastatic TNBC 
patients 
 
cohort: 55 years, 58% 
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visceral metastases, 61% had one or more prior systemic cancer therapies in 
a metastatic setting, and 88% had previously used taxanes.  
At a median follow-up of 24.4 months, the ORR was 39.4% (95% CI 22.9–
57.9), the median DOR was 9.1 months (95% CI 2.0–20.9), and the DCR was 
51.5% (95% CI 33.5–69.2). The median PFS and OS were 5.5 months (95% 
CI 5.1–7.7), and 14.7 months (95% CI 10.1–not estimable), respectively. Me-
dian PFS was numerically longer in patients treated in first-line versus sec-
ond-line setting (8.6 versus 5.1 months) and PD-L1-positive patients com-
pared with PD-L1-negative patients (6.9 versus 5.1 months). Similarly, me-
dian OS was numerically longer in patients treated in first-line versus sec-
ond-line setting (24.2 versus 12.4 months) and PD-L1-positive patients 
compared with PD-L1-negative patients (21.9 versus 11.4 months). 
All patients experienced at least one or more treatment-related AEs; 73% 
experienced grade 3 or 4 events, and 21% had grade 3 or 4 AESI. The com-
monly reported AEs were neutropenia (70%), fatigue (67%), alopecia (42%), 
diarrhoea (39%), peripheral sensory neuropathy (36%), peripheral neuropa-
thy (30%), and nausea (30%). The most frequent AEs of grade 3 or 4 severity 
attributed entirely to atezolizumab were diarrhoea (6%) and colitis (3%).  
 
 
8 Estimated costs 
A0021: What is the reimbursement status of atezolizumab? 
In Austria, atezolizumab is available in single-use 1200 mg/20mL vials of 60 
mg/mL concentrate solution for infusion for € 4,799.20 (ex-factory price) 
[28]. IMpassion130 patients received 840 mg of atezolizumab on days 1 and 
15 of every 28-day cycle [3], at a cost of approximately € 9,598.40 per cycle. A 
median duration of 24.1 weeks, or 6 months, of atezolizumab would cost ap-
proximately € 57,590.40. Patients also receive 100 mg/m2 nab-paclitaxel IV 
on days 1, 8, and 15 of every 28-day cycle for six cycles or more [3]. Assum-
ing an average body surface area of 1.70 m
2
, 170 mg of nab-paclitaxel would 
be needed per dose at a cost of € 533.12/dose and € 1,599.36/cycle [27]. A six 
month course of atezolizumab in combination with nab-paclitaxel would 
cost approximately € 67,186.56. Since TNBC accounts for 15–20% of breast 
cancers and 822–1,096 persons are diagnosed with TNBC in Austria annual-
ly, atezolizumab in combination with nab-paclitaxel would cost approxi-
mately € 55,227,352.00 to € 73,636,470.00 per year. Additional costs to assess 
PD-L1 status and to treat AEs will incur. If the expected target population is 
PD-L1 positive patients only, costs could be less.  
 
 
9 Ongoing research 
Several studies are ongoing to evaluate the use of atezolizumab in combina-
tion with other therapies for previously untreated metastatic and aTNBC. 
In February 2019, searches of www.clinicaltrials.gov and 
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www.clinicaltrialsregister.eu using the search terms “atezolizumab” and 
“triple negative breast cancer” yielded 28 other registered studies (six 
phase III, eleven phase II, four phase I/II, and seven phase I studies). Most 
studies were industry-sponsored or conducted in collaboration with indus-
try.  
Selected ongoing phase II and III studies evaluating neoadjuvant atezoli-
zumab and nab-paclitaxel followed by doxorubicin and cyclophosphamicde 
in early TNBC, atezolizumab and chemotherapy as neoadjuvant therapy 
prior to surgery for TNBC, atezolizumab plus carboplatin and nab-
paclitaxel in locally advanced TNBC, paclitaxel with or without atezoli-
zumab for aTNBC atezolizumab in combination with etinostat for aTNBC, 
atezolizumab with chemotherapy for recurrent TNBC, atezolizumab plus 
cobimetinib or cobimetinib and nab-paclitaxel for metastatic TNBC: 
 NCT02708680: is a phase I/II, randomized, double-blind, interven-
tional study to assess the efficacy of etinostat in combination with 
atezolizumab in patients with aTNBC. Estimated study completion 
date is January 2020. 
 NCT02322814: is a phase II, randomized, open-label, multi-stage, 
interventional study to assess the safety and efficacy of cobimetinib 
plus paclitaxel, cobimetinib plus atezolizumab plus paclitaxel, or 
cobimetinib plus atezolizumab plus nab-paclitaxel as first-line 
treatment for metastatic TNBC. Estimated study completion date is 
April 2020. 
 NCT03371017: IMpassion132 is a phase III, randomized, double-
blind, interventional study to compare the safety and efficacy of 
atezolizumab plus chemotherapy versus placebo plus chemotherapy 
in patients with inoperable, recurrent TNBC. Estimated study 
completion date is January 2021.  
 NCT03125902: IMpassion131 is a phase III, randomized, double-
blind, interventional study to evaluate the efficacy and safety of 
atezolizumab in combination with paclitaxel compared with place-
bo plus paclitaxel in patients with previously untreated, inoperable 
locally advanced or metastatic TNBC. Estimated study completion 
date is June 2021.  
 NCT03197935: IMpassion031 is a phase III, randomized, double-
blind, interventional study evaluating the safety and efficacy of ne-
oadjuvant atezolizumab and nab-paclitaxel followed by doxorubicin 
and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC 
in patients eligible for surgery with early TNBC. Estimated study 
completion date is September 2021.  
 NCT02620280: NeoTRIPaPDL1 is a phase III, randomized, open-
label, interventional study evaluating the addition of atezolizumab 
to carboplatin and nab-paclitaxel in patients with early high-risk 
and aTNBC compared to carboplatin and nab-paclitaxel. Estimated 
study completion date is October 2022.  
 NCT03281954: is a phase III, randomized, double-blind, interven-
tional study to compare the effectiveness of chemotherapy plus ate-
zolizumab versus chemotherapy plus placebo given as neoadjuvant 
therapy prior to surgery TNBC. Estimated study completion date is 
June 2024.  
16 phase II/III studies 
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 NCT03498716: IMpassion030 is a phase III, randomized, open-
label, interventional study comparing the effectiveness of atezoli-
zumab in combination with adjuvant anthracycline/taxane-based 
chemotherapy versus chemotherapy alone in patients with operable 
TNBC. Estimated study completion date is December 2024. 
 NCT01898117: Triple-B is a phase II, randomized, open-label, in-
terventional study comparing the effectiveness of carboplatin plus 
cyclophosphamide versus paclitaxel with or without atezolizumab 
as first-line treatment for aTNBC. Estimated study completion date 
is December 2029. 
 
 
10 Discussion 
Between 2016 and 2018, both the FDA and the EMA licensed atezolizumab 
as monotherapy for previously treated metastatic NSCLC, and for pre-
treated or cisplatin-ineligible MUC regardless of PD-L1 status. The FDA 
approved atezolizumab in combination with bevacizumab, paclitaxel and 
carboplatin as first-line treatment for metastatic NSCLC without EGFR or 
ALK aberrations in December 2018. Combination atezolizumab plus nab-
paclitaxel is currently under consideration by the FDA and EMA as initial 
treatment for patients with PD-L1-positive metastatic or aTNBC based on 
interim results of a phase III study [12-14].  
IMpassion130, a randomised, double-blind, phase III study investigated 
whether adding atezolizumab to nab-paclitaxel prolonged PFS and OS in 
902 treatment-naïve aTNBC patients. Stratified by baseline liver metastases, 
neoadjuvant or adjuvant taxane treatment, and PD-L1 status, patients were 
randomised 1:1 to 840 mg atezolizumab IV or placebo IV on days 1 and 15 
plus 100 mg/m
2
 nab-paclitaxel IV on days 1, 8, and 15 of every 28-day cycle 
until disease progression or toxicity. Adding atezolizumab increased the rate 
of PFS by 6%, prolonged PFS by 1.7 months, and reduced the risk of pro-
gression or death by 20% compared to chemotherapy alone. The PFS benefit 
was observed across most subgroups defined based on trial stratification. In 
the PD-L1-positive subgroup, adding atezolizumab increased the rate of 
PFS by 13%, prolonged survival by 2.5 months, and reduced the risk of pro-
gression or death by 38% compared to nab-paclitaxel alone. Adding atezoli-
zumab numerically increased OS by 3.7 months and reduced the risk of 
death in the ITT population by 16% at a 12.9-month follow-up; however, sta-
tistically there was no statistically significant difference between groups. 
While not formally tested in the PD-L1-positive population, atezolizumab 
increased OS by 9.5 months, potentially reducing the risk of death by 38% in 
this subgroup. Combination atezolizumab also increased the ORR and DOR 
in the ITT and PD-L1-positive subgroup compared to chemotherapy alone 
(10% versus 16%; 1.8 months versus 3.0 months, respectively).  
AEs were more commonly reported in the atezolizumab- than placebo com-
bination group, regardless of attribution (99.3% versus 97.9%, respectively). 
The most common grade 3 or 4 AEs with atezolizumab plus nab-paclitaxel 
were neutropenia, decreased neutrophils, peripheral neuropathy, fatigue and 
anaemia. Immune-mediated AEs were reported in 57% of atezolizumab 
combination patients versus 42% of placebo combination patients. Immune-
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related hypothyroidism and pneumonitis occurred more frequently in the 
atezolizumab group, and three deaths were attributed to autoimmune hepa-
titis, mucosal inflammation and septic shock. Grade 3 or 4 peripheral neu-
ropathy was more common in patients receiving atezolizumab versus place-
bo. AEs leading to dose interruption or discontinuation of atezolizumab 
treatment occurred in 31% and 6% of atezolizumab combination recipients, 
respectively.      
The results of IMpassion130 hold some limitations. Follow-up is insufficient 
to evaluate OS and long-term safety. No evidence was reported regarding the 
effect of atezolizumab combination on generic or disease specific QoL or the 
development of anti-therapeutic antibodies. Mature OS data, disease-
specific QoL measures, and a PD-L1 threshold of >10% are needed to en-
sure patients achieve a clinically relevant benefit over time despite manage-
able toxicity. The large confidence intervals associated with some subgroup 
analyses such as that for the African-American, baseline brain metastases, 
and lymph node only disease suggest a larger sample would be needed to 
gain greater precision regarding the effect of these factors on outcomes.  
Generalizability may be limited in that the study population had a median 
age of 56 years, good performance status (ECOG ≤1), and had adequate he-
matologic and end-organ function. Patients with CNS or autoimmune dis-
ease were excluded from study, and some subgroups had small sample sizes. 
The applicability of these study results for patients with higher ECOG per-
formance status, older age, co-morbidities, co-medications, African Ameri-
can race, baseline brain metastases, lymph node-only disease, or autoim-
mune disease needs further evaluation. While the dosage of atezolizumab 
used in this study is less than that recommended for the treatment of 
NSCLC or MUC, it is consistent with the dosage used to treat TNBC in 
phase I trials [31, 32]. While there is no standard specific chemotherapy for 
TNBC, an anthracycline, alkylator-, and taxane-based therapies are com-
monly used. Without direct comparison studies, physicians and patients 
may need to consider whether adding atezolizumab to nab-paclitaxel thera-
py would offer greater individualised efficacy than other available treat-
ments.  
IMpassion130 is a phase III trial with only a few methodological limitations. 
There was no risk of bias in the generation of randomisation sequence or al-
location concealment. Patients were randomly assigned 1:1 to atezolizumab 
combination or placebo combination using a centralized, automated interac-
tive voice or web response system [3]. Patients, physicians, and outcome as-
sessors were blinded as randomisation and allocation were centralized, 
matching placebo was used and all were blind to PD-L1 status. Selective re-
porting is unlikely as the co-primary endpoints of PFS and OS, and second-
ary endpoints of ORR, DOT were reported for the ITT and PD-L1-positive 
subpopulation as per protocol. Other endpoints not included in the interim 
analysis were anti-therapeutic antibodies, time to deterioration in global 
health status and health-related quality of life as per protocol. The risk of 
bias may be increased due to industry involvement in funding the study, col-
lecting, analysing and interpreting data, and funding editorial assistance. 
IMpassion130 
limitations: lack of data 
regarding OS, QoL, long-
term safety, small 
sample size for relevant 
subgroup analysis 
limited generalizability 
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The efficacy and safety data from IMpassion130 are consistent with previ-
ously reported phase I studies that suggest atezolizumab, either statistically 
significantly or numerically, increases PFS, OS, ORR and DOR in untreated 
metastatic TNBC patients and PD-L1-positive subgroups [31, 32]. Results 
confirm that, in general, patients who received atezolizumab as first-line 
therapy, those with PD-L1 expression of at least 1% on IC, and those with 
>10% IC were independently more likely to have higher ORR and longer 
PFS and OS than those that receive atezolizumab as second-line therapy, 
those with PD-L1 expression of <1% and those with <10% IC. Safety re-
sults were similar in that most treatment-related AEs occurred within one 
year of treatment, including neutropenia, cough, nausea, pyrexia, and im-
mune-mediated AEs; no new AEs were observed. 
Several studies are ongoing to evaluate atezolizumab in combination with 
other therapies as adjuvant treatment in early TNBC, and in the advanced, 
metastatic, and recurrent settings. While no immune checkpoint therapies 
are currently approved for TNBC, studies are also underway to explore the 
role of avelumab, durvalumab and pembrolizumab in metastatic TNBC [20, 
38]. In the absence of a standard chemotherapy regimen specific to TNBC or 
direct comparison trials, preference for treatment may lie in therapeutic op-
tions that pose less risk for toxicity.  Further studies are needed to identify 
new predictive immune biomarkers to identify potential responders. 
Given the non-curative setting of atezolizumab and the statistically signifi-
cant co-primary endpoint PFS, we applied Form 2b of the ESMO-MCBS in 
order to assess whether atezolizumab satisfies the criteria for a “meaningful 
clinical benefit” (score 4 or 5). OS in the ITT population was not statistically 
significant and formal testing of OS in the PD-L1-positive subgroup was not 
conducted at interim analysis. Both the original and adapted versions of the 
MCBS were applied. The application of the ESMO-MCBS to the IMpas-
sion130 study resulted in a grade 1 in the ITT population and a grade 3 in 
the PD-L1-positive subpopulation based on both the original and adapted 
versions of the ESMO-MCBS. Therefore, atezolizumab does not lead to a 
meaningful clinical benefit neither with the original nor adapted framework.  
In Austria, atezolizumab is available in single-use 1,200 mg/mL vials of 60 
mg/mL concentrate solution for infusion at an ex-factory price of € 4,799.20 
[28]. At a recommended dose of 840 mg twice per 28-day cycle, atezolizumab 
would cost approximately of € 9,598.40 per cycle; a median duration of six 
months would cost € 57,590.40. Atezolizumab is administered in combina-
tion with six or more cycles of nab-paclitaxel (100mg/m
2
) at a cost of € 
1,599.36/cycle [27]. A 6 month course of atezolizumab in combination with 
nab-paclitaxel would cost approximately € 67,186.56. Since TNBC accounts 
for 15–20% of breast cancers and 822–1096 persons are diagnosed with 
TNBC in Austria annually, atezolizumab in combination with nab-
paclitaxel would cost approximately € 55,227,352.00 to € 73,636,470.00 per 
year. Additional costs to assess PD-L1 status and treat AEs will incur. If the 
expected target population is PD-L1 positive patients only, costs could be 
less. 
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Overall, IMpassion130 is the first phase III, randomised, double-blind study 
to demonstrate that adding atezolizumab to nab-paclitaxel as first-line ther-
apy for aTNBC prolongs PFS and reduces the risk of progression or death. 
The PFS benefit of atezolizumab combination over nab-paclitaxel alone was 
also notable in the PD-L1-positive subgroup. AEs were consistent with 
known safety profiles of each agent. These study results are consistent with 
previous reports suggesting first-line atezolizumab, PD-L1 expression ≥1, 
and >10% tumour-infiltrating IC are independently associated with in-
creased ORR and PFS. Mature OS data, QoL measures and a PD-L1 thresh-
old of > 10% are needed to ensure patients achieve a clinically relevant ben-
efit over time despite manageable toxicity. Further studies are needed to 
identify predictive immune biomarkers selective of responders, combination 
strategies that enhance tumour immunogenicity, and to determine whether 
these findings extend to other chemoimmunotherapy combinations. 
  
IMpassion130: 
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Table 3: Benefit assessment based on original ESMO-MCBS and adapted benefit assessment based on adapted ESMO-MCBS [35] 
ESMO-
MCBS 
Subgroup 
Active  
substance 
Indica-
tion 
Inten-
tion 
PE Form MG standard 
treatment 
Efficacy Safety 
AJ FM MG 
months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
ITT 
Atezoli-
zumab aTNBC NC 
PFS & 
OS* 2b
1 ≤6 months +1.7 
0.80  
(0.69–0.92) 
HR >0.65 1 
+6.5% grade 3–4 
AEs, +7.7 % dis-
continuation 
NA - 1 
Original 
ESMO-
MCBS 
ITT Atezoli-
zumab 
aTNBC NC PFS & 
OS* 2b
1 ≤6 months +1.7 
0.80  
(0.69–0.92) 
HR >0.65 1 - NA - 1 
Adapted 
ESMO-
MCBS 
PD-L1–
positive 
Atezoli-
zumab aTNBC NC 
PFS & 
OS* 2b
1 ≤6 months +2.5 
0.62  
(0.49–0.78) 
HR ≤0.65 AND 
Gain ≥1.5 months 
3 NA NA - 3 
Original 
ESMO-
MCBS 
PD-L1–
positive 
Atezoli-
zumab aTNBC NC 
PFS & 
OS* 2b
1 ≤6 months +2.5 
0.62  
(0.49–0.78) 
HR ≤0.65 AND 
Gain ≥1.5 months 
3 NA NA - 3 
Abbreviations: AJ = Adjustments, aTNBC = advanced triple-negative breast cancer, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, PE = 
primary endpoint, NA = not available, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life, * co-primary endpoints 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint 
of interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the 
exact same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically fa-
vours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and out-
comes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjust-
ments separately. 
                                                             
1
 PFS was used to generate the ESMO-MCBS score, as OS in the intention-to-treat population was not statistically significant and formal testing of OS in the PD-L1–positive sub-
group was not conducted at this interim analysis 
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Table 4: Administration and dosing of atezolizumab or placebo + nab-paclitaxel [3, 4, 13] 
 Atezolizumab + nab-paclitaxel Placebo + nab-paclitaxel 
Administration mode 
Atezolizumab IV infusions on days 1 
and 15, plus nab-paclitaxel (100 
mg/m2) IV infusions on days 1, 8, and 
15 of every 28-day cycle. First infusion 
is administered over 60 minutes, 30 
minutes for subsequent infusions [13].. 
Matching placebo [3] 
Description of packaging 
Single-use, 20-cc USP/Ph Eur type 1 
glass vial of colourless-light yellow, 
sterile, preservative-free liquid [3]. 
Matching placebo [3]. 
Total volume contained in packaging for sale 
1200 mg/20 mL per vial; formulated as 
60 mg/mL atezolizumab in 20 mM 
histadine acetate, 120 mM sucrose, 
0.04% polysorbate 20, pH 5.8 [3]. 
Matching placebo [3]. 
Dosing 
Atezolizumab (840 mg) via IV infu-
sion on days 1 and 15, plus nab-
paclitaxel (100 mg/m2) IV infusions on 
days 1, 8, and 15 every 28-day cycle; 
dose reduction not permitted.  Inter-
rupt for AEs; discontinued if withheld 
≥16 weeks or in case of life-
threatening IM AEs [3]. 
20 mL of vehicle without the antibody; 
dose reduction not permitted. Inter-
rupt for AEs; discontinued if withheld 
≥16 weeks or in case of life-threatening 
IM AEs [3]. 
Median treatment duration 
Until progression or unacceptable tox-
icity; median DOT: 24.1 weeks of ate-
zolizumab and 22.1 weeks of nab-
paclitaxel [13] 
Until progression or unacceptable tox-
icity; median DOT: 22.1 weeks of pla-
cebo and 21.8 weeks of nab-paclitaxel 
[13] 
Contraindications None [4] Matching placebo [3]. 
Drug interactions 
None reported; not given within 4 
weeks of immune checkpoint-
targeting therapies, systemic im-
munostimulants, or live, attenuated 
vaccines [4]. Risk of interactions with 
immune-modulating drugs; systemic 
corticosteroids may affect efficacy [2]. 
Matching placebo [3]. 
Abbreviations: AE = adverse events; cc = cubic centimetre; IM = immune mediated; IV = intravenous; mM = millimole; Ph Eur = pharmaco-
poeia European; USP = United States Pharmacopeia  
Atezolizumab with nab-paclitaxel for the treatment of advanced triple-negative breast cancer (aTNBC) 
LBI-HTA | 2019 33 
Table 5: Characteristics of the Impassion130 [13] 
Title: Atezolizumab and nab-paclitaxel in advanced TNBC [3, 13, 30] 
Study identifier NCT02425891, EudraCT 2014-005490-37, WO29522, Impassion130 
Design International (41 countries), multicentre (246 sites), randomised, double-blind, interventional 
phase III 
Median duration of treatment at da-
ta cut-off (April 17, 2018): 
Atezolizumab + nab-paclitaxel: 24.1 weeks (7 cycles) of 
atezolizumab and 22.1 weeks (cycles) of nab-paclitaxel 
placebo + nab-paclitaxel: 22.1 weeks (6 cycles) of placebo 
and 21.8 weeks (6 cycles) nab-paclitaxel 
Duration of enrolment phase: June 2015 – May 2017 
Median follow-up at data cut-off: 12.9 months in ITT; 13.0 months for atezolizumab + nab-
paclitaxel, 12.5 months for placebo + nab-paclitaxel 
Hypothesis 
Superiority 
The study was designed to evaluate the efficacy and safety of atezolizumab + nab-paclitaxel com-
pared with placebo + nab-paclitaxel for patients with previously untreated locally advanced or 
metastatic TNBC  
Funding Hoffmann-La Roche/Genentech, Celgene provided nab-paclitaxel 
Treatments groups 
 
Atezolizumab + nab-paclitaxel 
(ITTn = 451 efficacy; n = 452 safety) 
840 mg atezolizumab IV on day’s 1 and 15, and 100 mg/m2 
nab-paclitaxel IV on days 1, 8 and 15 of each 28-day cycle 
for > 6 cycles without maximum. Both agents were ad-
ministered until progression or unacceptable toxicity.  
Placebo + nab-paclitaxel 
(ITTn = 451 efficacy; n = 438 safety) 
Placebo IV on day’s 1 and 15 and 100 mg/m2 nab-paclitaxel 
IV on days 1, 8 and 15 of each 28-day cycle for > 6 cycles 
without maximum. Both agents were administered until 
progression or unacceptable toxicity.  
Notes 
After disease progression per RECIST v1.1, study treatment 
assignment may be unblinded and patients randomised to 
atezolizumab + nab-paclitaxel may continue receiving 
open-label atezolizumab with or without nab-paclitaxel. 
Patients taking placebo + nab-paclitaxel were discontinued 
from treatment as crossover to atezolizumab was not al-
lowed.   
Endpoints and definitions 
 
Progression-free survival 
(all randomized patients) 
C0-primary endpoint  
PFS Time from randomization to radiographic progression ac-
cording to RECIST (v1.1) or all-cause death in all random-
ized participants. Time frame: baseline up to 53 months, 
assessed at screening, every 8 weeks for first 12 months, 
every 12 weeks until progression or death). 
Progression-free survival 
(PD-L1+ patients) 
Co-primary endpoint  
PFS Time from randomization to radiographic progression ac-
cording to RECIST (v1.1) or all-cause death in participants 
with detectable PD-L1. Time frame: baseline up to 53 
months, assessed at screening, every 8 weeks for first 12 
months, every 12 weeks until progression or death). 
Overall survival 
(all randomized patients) 
C0-primary endpoint 
OS Time from randomization to all-cause death in all random-
ized participants. Time frame: baseline until death due to 
any cause (up to 53 months). 
Overall survival 
(PD-L1+ patients) 
Co-primary endpoint 
OS Time from randomization to all-cause death in participants 
with detectable PD-L1. Time frame: baseline until death 
due to any cause (up to 53 months). 
Objective response rate  
(all randomized patients) 
Secondary endpoint 
ORR 
Percentage of participants with an objective response, 
complete response (CR) or partial response (PR), accord-
ing to RECIST v1.1 in all randomized participants. Time 
frame: baseline up to 53 months, assessed at screening, 
every 8 weeks for first 12 months, every 12 weeks until 
progression or death). 
Objective response rate  
(PD-L1+ patients) 
Secondary endpoint 
ORR 
Percentage of participants with an objective response, 
complete response (CR) or partial response (PR), accord-
ing to RECIST v1.1 in participants with detectable PD-L1. 
Time frame: baseline up to 53 months, assessed at screen-
ing, every 8 weeks for first 12 months, every 12 weeks until 
progression or death). 
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Title: Atezolizumab and nab-paclitaxel in advanced TNBC [3, 13, 30] 
Study identifier NCT02425891, EudraCT 2014-005490-37, WO29522, Impassion130 
Duration of response 
(all randomized patients) 
Secondary endpoint 
DOR 
Time from randomization to first occurrence of an objec-
tive response to RECIST v1.1 progression or all-cause death 
for patients with an objective response in all randomized 
participants. Time frame: baseline up to 53 months, as-
sessed at screening, every 8 weeks for first 12 months, eve-
ry 12 weeks until progression or death). 
Duration of response 
(PD-L1+ patients) 
Secondary endpoint 
DOR 
Time from randomization to first occurrence of an objec-
tive response to RECIST v1.1 progression or all-cause death 
for patients with an objective response in participants with 
detectable PD-L1. Time frame: baseline up to 53 months, 
assessed at screening, every 8 weeks for first 12 months, 
every 12 weeks until progression or death). 
Time to deterioration 
(all randomized patients) 
Secondary endpoint 
TTD 
Time to deterioration in GHS/HRQoL according to EORTC 
QLQ-C30 v3.0 in all randomized participants. Time frame: 
baseline up to 53 months, assessed day 1 of each cycle up 
to treatment discontinuation, every 28 days after discon-
tinuation for 1 year (overall approximately 53 months).  
Time to deterioration 
(PD-L1+ patients) 
Secondary endpoint 
TTD 
Time to deterioration in GHS/HRQoL according to EORTC 
QLQ-C30 v3.0 in participants with detectable PD-L1. Time 
frame: baseline up to 53 months, assessed day 1 of each cy-
cle up to treatment discontinuation, every 28 days after 
discontinuation for 1 year (overall approximately 53 
months).  
Adverse events 
Secondary endpoint 
AE 
Percentage of participants with adverse events or serious 
adverse events (SAE) according to CTCAE version 4.0.  
Antitherapeutic antibod-
ies 
Secondary endpoint 
ATAs 
Percentage of participants with anti-therapeutic antibod-
ies against atezolizumab. Time frame: baseline up to 53 
months, assessed at per dose (hour0) on day 1 of cycles 1, 
2, 3, 4, 8, 16, and every 8 cycles thereafter up to treatment 
discontinuation (approximately 53 months), 120 days after 
last dose (approximately 53 months).  
Database lock Last update posted December 10, 2018 
Results and Analysis  
Analysis description Primary Analysis 
ITT: two efficacy endpoints, investigator-assessed PFS and OS, were evaluated in all randomized patients 
and subgroup analyses were performed on PD-L1 positive patients.  Safety data included all patients who 
received at least one dose of treatment. Two interim analyses and a final analysis of OS were planned. 
Type I error (0.05) was controlled and split between the analyses of PFS (0.01) and OS (0.04), with hier-
archical testing for OS first in the ITT population, then in PD-L1 positive subgroup (95% power for PFS in 
ITT population, 88% power for OS analysis).       
PFS and OS were compared using a stratified log-rank test. HRs for disease progression and death were 
estimated using a stratified Cox proportional-hazards model. Kaplan-Meier analysis was applied to PFS 
and OS, and Brookmeyer-Crowley method was used to construct the 95% CI for each median duration. 
Similar methods were applied to the DOR and the analysis was not stratified. Comparisons of the RR be-
tween groups were made using the stratified Cochran-Mantel-Haenszel test.  
Analysis population   
Inclusion 
 Adults ≥ 18 years of age with metastatic or locally advanced, histologi-
cally documented TNBC characterized by absence of HER2, ER, and PR 
expression 
 No prior chemotherapy or targeted systemic therapy for inoperable lo-
cally advanced or metastatic TNBC 
 Eligible for taxane monotherapy (absence of rapid clinical progression, 
life-threatening visceral metastases, or need for rapid symptom and/or 
disease control) 
 Representative formalin-fixed, paraffin-embedded tumour specimen in 
paraffin blocks, or at least 20 unstained slides with associated pathology 
report documenting ER, PR, and HER2 negativity. Participants with 
fewer than 20 unstained slides available at baseline, and not fewer than 
12 unstained slides will be eligible upon discussion with Medical Monitor.  
 ECOG performance status of 0 or 1 
 Measurable disease as defined by RECIST v1.1 
 Adequate hematologic and end-organ function 
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Title: Atezolizumab and nab-paclitaxel in advanced TNBC [3, 13, 30] 
Study identifier NCT02425891, EudraCT 2014-005490-37, WO29522, Impassion130 
 
Exclusion 
 Known CNS disease, except treated asymptomatic CNS metastases 
 Leptomeningeal disease 
 Pregnancy or lactation 
 History of autoimmune disease 
 Prior allogeneic stem cell or solid organ transplant 
 Positive test for human immunodeficiency virus 
 Active hepatitis B or hepatitis C 
 Receipt of a live, attenuated vaccine within 4 weeks prior to randomiza-
tion, during treatment, or within 5 months following the last dose of 
atezolizumab/placebo 
 
Characteristics 
 
ITT 
Atezolizumab + 
Nab Paclitaxel 
(n = 451) 
ITT 
Placebo + Nab-
Paclitaxel 
(n = 451) 
PD-L1-Positive 
Atezolizumab + 
Nab Paclitaxel 
(n = 185) 
PD-L1-Positive 
Placebo + Nab-
Paclitaxel 
(n = 184) 
Median age (range), years 
  18-40 years, n (%) 
  41-64 years, n (%) 
  ≥ 65 years 
55 (20–82) 
63 (14.0) 
284 (63.0) 
104 (23.1) 
56 (26–86) 
51 (11.3) 
285 (63.2) 
115 (25.5) 
53 (26–82) 
31 (16.8) 
111 (60.0) 
43 (23.2) 
53 (28–85) 
24 (13.0) 
117 (63.6) 
43 (23.4) 
Female, n (%) 448 (99.3) 450 (99.8) 184 (99.5) 184 (100) 
Race, n (%) 
  Caucasian 
  Asian 
  African American 
  Native American 
  Hawaiian/Pacific  
  Multiple 
  Unknown 
 
308 (68.3) 
85 (18.8) 
26 (5.8) 
17 (3.8) 
1 (0.2) 
2 (0.4) 
12 (2.7) 
  
301 (66.7) 
76 (16.9) 
33 (7.3) 
23 (5.1) 
0 (0.0) 
3 (0.7) 
15 (3.3) 
  
125 (67.6) 
38 (20.5) 
9 (4.9) 
8 (4.3) 
0 (0.0) 
0 (0.0) 
5 (2.7) 
  
129 (70.1) 
28 (15.2) 
14 (7.6) 
9 (4.9) 
0 (0.0) 
0 (0.0) 
4 (2.2) 
ECOG performance-status, 
n/N (%) 
  0 
  1 
  2 
 
 
256/450 (56.9) 
193/450 (42.9) 
1/450 (89.9) 
 
 
270/450 (60.0) 
179/450 (39.8) 
1/450 (90.7)  
  
 
107/185 (57.8) 
77/185 (41.6) 
1/185 (0.5) 
 
 
112/184 (60.9) 
72/184 (39.1) 
0 (0.0) 
Metastatic, n /N (%) 
No of sites, n/N (%) 
  0-3 
  ≥ 4 
404/450 (89.8) 
 
332/450 (73.8) 
118/450 (26.2) 
408/450 (90.7) 
 
341/449 (75.9) 
108/449 (24.1) 
162/185 (87.6) 
 
149/185 (80.5) 
36/185 (19.5) 
159/183 (86.9) 
 
140/183 (76.5) 
43/183 (23.5) 
Site of metastases 
  Liver, n (%) 
  Bone, n (%) 
  Brain, n (%) 
  Lung, n (%) 
  Lymph-only, n/N (%) 
 
126 (27.9) 
145 (32.2) 
30 (6.7) 
226 (50.1) 
33/450 (7.3) 
 
118 (26.2) 
141 (31.3) 
31 (6.9) 
242 (53.7) 
23/449 (5.1) 
 
44 (23.8) 
54 (29.2) 
15 (8.1) 
86 (46.5) 
18/185 (9.7) 
 
39 (21.2) 
49 (26.6) 
11 (6.0) 
98 (53.3) 
13/183 (7.1) 
Previous therapy, n (%) 
Neoadjuvant or adjuvant 
therapy, n (%) 
Taxane 
Anthracycline 
 
 
284 (63.0) 
231 (51.2) 
243 (53.9) 
 
 
286 (63.4) 
230 (51.0) 
242 (53.7) 
 
 
125 (67.6) 
96 (51.9) 
109 (58.9) 
 
 
117 (63.6) 
94 (51.1) 
101 (34.3) 
Applicability of evidence 
Population 
IMpassion130 was conducted in treatment naïve TNBC patients with a median age of 56 years, good per-
formance status, and adequate hematologic and end-organ function. The applicability of these results for 
patients with higher ECOG performance-status, CNS or autoimmune disease, and those with small sub-
group sample sizes (African American race, baseline brain metastases, and lymph node only disease) 
needs further evaluation.  
Intervention 
While the dosage of atezolizumab recommended for the treatment of TNBC is less than that recom-
mended for NSCLC or MUC, it is consistent with the dosage used to treat TNBC in phase I studies [31, 32]. 
Dose interruptions were allowed for any potentially study drug-related events and discontinued if toxici-
ties persist.  
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Title: Atezolizumab and nab-paclitaxel in advanced TNBC [3, 13, 30] 
Study identifier NCT02425891, EudraCT 2014-005490-37, WO29522, Impassion130 
Comparators 
While there is no standard, specific chemotherapy for TNBC, an anthracycline, alkylator-, and taxane-
based chemotherapies are commonly used. Without direct comparison trials, physicians and patients may 
need to discuss whether adding atezolizumab to nab-paclitaxel therapy would provide greater individual-
ised efficacy than other treatment options.  
Outcomes 
Follow-up is insufficient to assess OS and long-term safety. Mature OS data and disease-specific QoL 
measures are needed to ensure patients achieve a clinically relevant benefit over time despite managea-
ble toxicity.  
Setting IMpassion130 is a multinational study conducted in 246 sites in 41 countries.  
Abbreviations: AE = adverse events; ATAs = anti-therapeutic antibodies; CR = complete response; CTCAE = Common Terminology Criteria for 
Adverse Events; ECOG = Eastern Cooperative Oncology Group; EORTC = European Organisation for Research and Treatment of Cancer; ER 
= oestrogen receptor; GHS = global health status; HER2 = human epidermal growth factor 2; HR = hazard ratio; HRQoL = health related 
quality of life; ITT = intention-to-treat;  MUC = metastatic urothelial cancer; NSCLC = non-small cell lung cancer; ORR = objective response 
rate; OS = overall survival; PD-L1 = programmed death ligand 1; PFS = progression-free survival; PR = progesterone receptor; QLQ-C30 = 
Quality-of-Life Questionnaire Core 30; RECIST = Response Evaluation Criteria in Solid Tumours; RR = relative risk; TNBC = triple-negative 
breast cancer 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA (Internal validity of randomised controlled trials) [33] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: permuted block-randomized to 1:1 atezoli-
zumab + nab-paclitaxel vs placebo + nab-paclitaxel via centralised interactive voice or web-
based response system (IxRS). An external independent statistical coordinating centre verified 
patient randomization and study treatment kit assignments. Randomisation was stratified by 
presence of liver metastases (yes vs no), prior taxane treatment (yes vs no), and PD-L1 ex-
pression on tumour-infiltrating immune cells as a percentage of tumour area (<1% PD-L1 
negative vs ≥  1% PD-L1 positive). Patients received their first dose of study drug within 3 days 
of randomisation. 
yes 
Adequate allocation concealment: IxRS generated random allocation sequence. yes 
Blinding: 
Patient: centralised randomisation and allocation; unaware of PD-L1 sta-
tus and treatment assignment. 
yes 
Treating physician: centralised randomisation and allocation; site person-
nel were unaware of patients’ PD-L1 status and treatment assignment. 
yes 
Outcome assessment: centralised randomisation and allocation; investiga-
tor-assessed PFS and OS were co-primary endpoints where investigators 
were blind to PD-L1 status and treatment assignment; sensitivity analysis 
included ICE-assessed PFS.  
yes 
Selective outcome reporting unlikely: co-primary endpoints PFS and OS (ITT and PD-L1-
positive), secondary endpoints of ORR, DOR (ITT and PD-L1 positive) were reported. Other 
endpoints not included in this analysis are TTD in GHS/HRQoL, as per protocol.  
yes 
No other aspects which increase the risk of bias: industry sponsored the study, provided study 
drugs, assisted in trial design, data collection, analysis and interpretation. The sponsor also 
funded editorial assistance from professional medical writers. Trial sponsor was unaware of 
patients’ PD-L1 status. 
no 
Risk of bias – study level low-risk 
Abbreviations: DOR = duration of response; GHS = global health status; HRQoL = health-related quality of life; ICR = independent cen-
tral review; IT = intention-to-treat; IxRS = interactive voice or web response system; PFS = progression-free survival; ORR: overall re-
sponse rate; OS = overall survival; TTD = time to deterioration 
 
 
 
